(Q37910906)

25 August 2017

1 reference

title

Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy (English)

1 reference

25 August 2017

1 reference

Daniel P Judge

1

1 reference

25 August 2017

David A Kass

series ordinal

2

1 reference

25 August 2017

W Reid Thompson

series ordinal

3

1 reference

25 August 2017

Kathryn R Wagner

series ordinal

4

1 reference

25 August 2017

publication date

1 October 2011

1 reference

American journal of cardiovascular drugs

25 August 2017

published in

1 reference

25 August 2017

volume

11

1 reference

25 August 2017

issue

5

1 reference

25 August 2017

page(s)

287-294

1 reference

https://scigraph.springernature.com/pub.10.2165/11594070-000000000-00000

25 August 2017

exact match

0 references

cites work

Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Current treatment of adult Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Dystrophin: the protein product of the Duchenne muscular dystrophy locus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Membrane organization of the dystrophin-glycoprotein complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

SMAD signaling drives heart and muscle dysfunction in a Drosophila model of muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Carvedilol can prevent cardiac events in Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Eplerenone in patients with systolic heart failure and mild symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Nitric oxide in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Localization of nitric oxide synthase indicating a neural role for nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Sarcolemma-localized nNOS is required to maintain activity after mild exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Role of nitric oxide in the pathogenesis of muscular dystrophies: a "two hit" hypothesis of the cause of muscle necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Between channels and tears: aim at ROS to save the membrane of dystrophic fibres

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Streptomycin reduces stretch-induced membrane permeability in muscles from mdx mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

TRPC1 binds to caveolin-3 and is regulated by Src kinase - role in Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Regulation of capacitative calcium entries by alpha1-syntrophin: association of TRPC1 with dystrophin complex and the PDZ domain of alpha1-syntrophin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

TRPC3-interacting triadic proteins in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

A common mechanism underlies stretch activation and receptor activation of TRPC6 channels

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Overview of PDEs and their regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Purification of cGMP-binding protein phosphodiesterase from rat lung

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Dystrophic heart failure blocked by membrane sealant poloxamer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594070-000000000-00000

10.2165/11594070-000000000-00000

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

1042024752

0 references

1 reference